Premium
OUTCOMES IN FIRST RELAPSED‐REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE‐FIRST STUDY
Author(s) -
Visco C.,
Di Rocco A.,
Tisi M.C.,
Morello L.,
Evangelista A.,
Zilioli V.R.,
Rusconi C.,
Hohaus S.,
Sciarra R.,
Re A.,
Tecchio C.,
Chiappella A.,
MarinNiebla A.,
McCulloch R.,
Gini G.,
Perrone T.,
Nassi L.,
Pennese E.,
Stefani P.M.,
Cox M.C.,
Bozzoli V.,
Fabbri A.,
Polli V.,
Ferrero S.,
De Celis I.A.,
Sica A.,
Arcaini L.,
Balzarotti M.,
Rule S.,
Vitolo U.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.16_2629
Subject(s) - bendamustine , mantle cell lymphoma , medicine , ibrutinib , rituximab , cytarabine , salvage therapy , progression free survival , oncology , autologous stem cell transplantation , population , refractory (planetary science) , transplantation , surgery , gastroenterology , chemotherapy , lymphoma , leukemia , chronic lymphocytic leukemia , physics , environmental health , astrobiology